| Oct 9 |
Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Oct 8 |
Amneal to Report Third Quarter 2024 Results on November 8, 2024
|
| Oct 1 |
Amneal and Metsera collaborate to supply obesity and metabolic disease medicines
|
| Oct 1 |
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
|
| Sep 23 |
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
|
| Sep 6 |
Amneal raised to neutral by J.P. Morgan amid improved growth
|
| Sep 6 |
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
|
| Sep 5 |
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
|
| Aug 20 |
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
|
| Aug 17 |
Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President Nikita Shah Sells ...
|
